Figure 6.

Ongoing RCTs of Nicotinamide in Patients With COVID-19

Niacin is being evaluated in different settings, including inpatient non-ICU, outpatient, and post-acute COVID-19 settings. ∗The full list of inclusion and exclusion criteria should be found in the original trial records. ^†Patient enrollment setting includes hospitalized non-ICU patients, outpatient, and post-acute COVID-19 settings. AKI = acute kidney injury; CNS = central nervous system; eGFR = estimated glomerular filtration rate; NAD = nicotinamide-adenine dinucleotide; RRT = renal replacement therapy; other abbreviations as in Figures 3 and 4. Full study names are provided in the text.